Perindopril vs Ramipril for Persistence in MAU Reduction Study

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators conducted a single center study controlled study involving 20 patients with Type 2 Diabetes and hypertension who were randomly assigned to receive ramipril 10mg or perindopril 8mg. The primary endpoint was difference in urine albumin-creatinine ratio at night time and during the day. Secondary endpoint was measurement of blood pressure.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sunnybrook Health Sciences Centre
• Collaborator: Servier
• Treatments: Perindopril; Ramipril

Criteria

Inclusion Criteria:

• Type 2 Diabetes,

• stable therapy with an ACEi or ARB for 8 weeks prior to screening period

• blood pressure controlled to < 130/80 mmHg

Exclusion Criteria:

• Pregnancy,

• dual therapy with ACEi and ARB 8 weeks prior to screening

• history of cough with ACEi

• hypersensitivity to either medication

• myocardial infarction within 12 weeks of screening

• congestive heart failure (NYHA Class IV)

• severe coronary artery disease

• severe liver disease

• renal artery stenosis.